跳到正文
Molecular Therapy· Satrusal·收录于· 6 天前

Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage

Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage

来源:Molecular Therapy · doi.org